top of page
News, Events and Updates
Search
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 12, 2022
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Dec 2, 2022
ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,
Dec 1, 2022
Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Nov 28, 2022
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Nov 23, 2022
Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
Nov 8, 2022
US FDA Orphan Drug Designation to ANAVEX®2-73 (blarcamesine) for the Treatment of Fragile X Syndrome
Nov 7, 2022
Anavex Life Sciences Announces Late-Breaking Presentation at the 2022 CTAD Congress
Oct 17, 2022
Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Sep 21, 2022
8
9
10
11
12
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
